Search for a trial

Molecular markers in biomaterial derived from patients with inflammatory bowel disease

Systematic gathering of biomaterial and phenotypic data of IBD patients during clinical care provides assessment of molecular markers in the DNA, the transcriptome and proteome. The markers can be associated with the different disease phenotypes…

Less Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple

The LIMONCELLO study aims to assess the effect and cost-effectiveness of TMPC compared to usual care.

Seizure Treatment IN Glioma (STING): comparing a treatment strategy with levetiracetam versus treatment with valproic acid in glioma patients with a first seizure

The overall aim of this strategy study is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with de novo seizures. In addition, we aim to examine the level of toxicity, the impact of seizures…

PeRcutaneous cOronary intervention of native Coronary arTery versus venous bypass graft in patients with prior cORonary artery bypass graft surgery - the PROCTOR trial

To compare the clinical and angiographic outcomes of a strategy of native vessel PCI with SVG PCI in patients with prior CABG presenting with SVG failure and a clinical indication for repeat revascularization, as determined by the local Heart Team.

The prospective data collection initiative on on small bowel, colorectal and anal cancer - a prospective observational cohort study.

The main objectives of this project are:- To start a prospective observational cohort study of patients who have been diagnosed with CRC, small bowel and anal cancer and follow them from time of diagnosis until death.- To prospectively collect data…

The safety and cost-effectiveness of discontinuing disease-modifying therapies in stable relapsing-onset multiple sclerosis (DOT-MS): a randomized rater-blinded multicenter trial.

The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…